RLX03O
Heart failure treatment given Breakthrough Status
June 27, 2013Sales and Marketing Breakthrough Therapy Designation, Novartis, RLX03O, serelaxin
Novartis’ new treatment for heart failure has been granted Breakthrough Therapy designation status by the FDA. RLX030 (serelaxin) is for …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
